Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.06) per share and revenue of $4.14 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%. The firm had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $3.99 million. On average, analysts expect Lexicon Pharmaceuticals to post ($0.17) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.
Lexicon Pharmaceuticals Stock Up 1.4%
Shares of LXRX opened at $1.44 on Tuesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 13.29 and a current ratio of 13.37. Lexicon Pharmaceuticals has a one year low of $1.10 and a one year high of $2.68. The stock has a market capitalization of $640.74 million, a price-to-earnings ratio of -9.60 and a beta of 1.07. The stock has a 50 day moving average price of $1.87 and a 200 day moving average price of $1.88.
Analyst Ratings Changes
Several equities research analysts have issued reports on LXRX shares. Cantor Fitzgerald began coverage on shares of Lexicon Pharmaceuticals in a research note on Monday, September 28th. They set an “overweight” rating and a $8.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 21st. Zacks Research cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.70.
Read Our Latest Report on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.
Lexicon’s commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.
Further Reading
- Five stocks we like better than Lexicon Pharmaceuticals
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
